SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders

通过特殊目的实体（SPV）CERO 1236，直接向子公司注入资本，且不稀释现有SRX Global股东的股权

Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies

拟议收购预计将加速CERo公司主要候选产品CER-1236在血液系统恶性肿瘤领域的开发

NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc.

佛罗里达州北棕榈滩，2026年10月7日（环球电讯社）——SRX Global Inc.（纽交所美国市场：SRXH）（以下简称“公司”或“SRX”）是一家致力于通过对高确信度的运营公司和战略资产进行投资来创造长期股东价值的人工智能赋能平台。该公司今日宣布，已签订具有约束力的购买协议，根据该协议，CERo Therapeutics（CERo Therapeutics Holdings, Inc. 的运营子公司）

(OTCQB: CERO) ('CERo Holdings' and, together with CERo Therapeutics, 'CERo'), an innovative cellular immunotherapy company advancing the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, will become a wholly owned subsidiary of SRX Global..

(OTCQB: CERO)（“CERo Holdings”，与 CERo Therapeutics 合称“CERo”）是一家创新的细胞免疫治疗公司，致力于推进采用吞噬机制的下一代工程化 T 细胞疗法，该公司将成为 SRX Global 的全资子公司。

The pending transaction is expected to accelerate the advancement of CERo's clinical programs. The combination of Cero and the CERO 1236 SPV is expected to benefit from enhanced access to capital. The transaction combines SRX Global's public company infrastructure with CERo's innovative oncology platform..

预计待完成的交易将加速CERo临床项目的推进。Cero与CERO 1236特殊目的载体（SPV）的合并有望受益于更便捷的资本获取渠道。该交易将SRX Global的上市公司基础设施与CERo的创新肿瘤学平台相结合。

Chief Executive Officer of SRX Global Inc., Kent Cunningham stated, 'This proposed acquisition reflects our strategy of investing in high-conviction operating companies with meaningful long-term value creation potential. CERo's differentiated approach to engineered T cell therapeutics, and the clinical progress the team has made with CER-1236, make it a compelling addition to our platform.

SRX Global Inc. 首席执行官 Kent Cunningham 表示：“此次拟议收购反映了我们的战略，即投资于具有高确定性且具备显著长期价值创造潜力的运营公司。CERo 在工程化 T 细胞疗法方面的差异化方法，以及其团队在 CER-1236 项目上取得的临床进展，使其成为我们平台极具吸引力的补充。”

We expect this transaction to give CERo enhanced access to capital and broader operational resources to support continued advancement of CER-1236 and its broader R&D efforts, while providing SRX shareholders exposure to an innovative oncology asset.'.

我们预计，此次交易将为CERo提供更便捷的资本渠道和更广泛的运营资源，以支持CER-1236的持续研发及其更广泛的研发工作，同时使SRX股东能够受益于这一创新的肿瘤学资产。

CERo Chief Executive Officer, Chris Ehrlich added, 'This proposed transaction represents an important development for CERo and our mission to develop potentially life-prolonging therapies for patients experiencing rare and difficult-to-treat cancers. By becoming part of SRX, we expect CERo Therapeutics to benefit from broader operational resources that can support the continued advancement of CER-1236 and our broader R&D efforts.

CERo 首席执行官 Chris Ehrlich 补充道：“此次拟议交易对 CERo 以及我们致力于为患有罕见且难治性癌症的患者开发可能延长生命的疗法这一使命而言，具有重要意义。通过加入 SRX，我们预计 CERo Therapeutics 将受益于更广泛的运营资源，从而支持 CER-1236 的持续进展以及我们更广泛的研发工作。”

We believe the proposed transaction provides a stronger platform from which to execute our clinical development strategy and create long-term value for patients and shareholders.'.

我们相信，拟议的交易将提供一个更强大的平台，以执行我们的临床开发战略，并为患者和股东创造长期价值。

Under the terms of the proposed transaction, Andrew ('Al') Kucharchuk, currently CERo Chief Financial Officer, is expected to serve as President of and primary executive of CERo Therapeutics following the closing of the proposed transaction. Chris Ehrlich and current CERo director Brian Atwood are each expected to serve on the CERo Therapeutics Board of Directors and as Special Advisors to the President.

根据拟议交易条款，CERo现任首席财务官安德鲁（“Al”）·库查丘克预计将在拟议交易完成后担任CERo Therapeutics的总裁兼首席执行官。克里斯·埃利希和CERo现任董事布莱恩·阿特伍德均预计将加入CERo Therapeutics董事会，并担任总裁特别顾问。

This leadership structure is intended to provide continuity for CERo Therapeutics operations..

该领导架构旨在为 CERo Therapeutics 的运营提供连续性。

To date, CERo has reported treating six patients in the ongoing Phase 1 CERTAIN-T trial. In the most recent cohort of three patients, CER-1236 was administered at an increased dose level, with no dose-limiting toxicities ('DLTs') observed during the DLT assessment period. As previously reported, CERo has also observed expansion of infused CER-1236 cells following administration, and CERo continues to evaluate the pharmacokinetic and pharmacodynamic profile of CER-1236 as the study advances through dose escalation.

迄今为止，CERo 报告称在正在进行的 1 期 CERTAIN-T 试验中已治疗了六名患者。在最近一组三名患者中，CER-1236 以更高的剂量水平给药，在剂量限制性毒性（DLT）评估期间未观察到剂量限制性毒性。正如之前所报道的，CERo 还观察到输注的 CER-1236 细胞在给药后出现扩增，随着研究通过剂量递增阶段推进，CERo 继续评估 CER-1236 的药代动力学和药效学特征。

These clinical results are preliminary and are not sufficient to establish the safety or efficacy of CER-1236..

这些临床结果是初步的，不足以确立CER-1236的安全性或有效性。

CERo has initiated the third planned cohort of the CERTAIN-T study, which is expected to evaluate the planned one billion cells/patient protocol and is currently screening patients for enrollment. The cohort is also expected to include patients with myelodysplastic syndromes ('MDS') and myelofibrosis ('MF'), reflecting CERo's strategy to further evaluate CER-1236 in additional myeloid disease settings..

CERo已启动CERTAIN-T研究的第三个计划队列，该队列预计将评估每患者十亿细胞的既定方案，目前正在进行患者入组筛查。该队列也有望纳入骨髓增生异常综合征（MDS）和骨髓纤维化（MF）患者，这反映了CERo旨在进一步在更多髓系疾病背景下评估CER-1236的战略。

About the CERTAIN-T Trial

关于CERTAIN-T试验

The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia ('AML'), including relapsed/refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML, and has since expanded to include transfusion-dependent myelodysplastic syndromes ('TD-MDS'), high-risk myelodysplastic syndromes ('HR-MDS'), and post-JAK inhibitor myelofibrosis ('MF').

首个人体、多中心、开放标签的1/1b期CERTAIN-T研究旨在评估CER-1236在血液系统恶性肿瘤患者中的安全性、耐受性、药代动力学、药效学及初步临床活性。该研究最初入组急性髓系白血病（AML）患者，包括复发/难治性AML、可测量残留病灶AML以及新诊断的TP53突变型AML，随后扩展至包括输血依赖性骨髓增生异常综合征（TD-MDS）、高危骨髓增生异常综合征（HR-MDS）以及JAK抑制剂治疗后的骨髓纤维化（MF）患者。

Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate ('ORR'), complete response ('CR'), composite complete response ('cCR'), and measurable residual disease ('MRD')..

主要终点包括安全性和耐受性。次要终点包括药代动力学和临床反应指标，包括总缓解率（ORR）、完全缓解（CR）、复合完全缓解（cCR）和可测量残留病灶（MRD）。

About SRX Global Inc.

关于SRX全球公司

SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors..

SRX Global 是一个由人工智能驱动的平台，专注于通过对高确信度的运营公司、战略性资产以及技术赋能的机会进行投资，创造长期的股东价值。该公司利用专有技术、数据分析和严谨的资本配置，在多个领域识别并管理投资。

About CERo Therapeutics Holdings, Inc.

关于CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The company's proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer.

CERo Therapeutics Holdings, Inc. 是一家创新的免疫治疗公司，致力于推进工程化T细胞疗法的开发，用于癌症治疗。该公司专有的T细胞工程技术旨在将先天免疫和适应性免疫的特征整合到单一的治疗结构中，以调动多种免疫机制对抗癌症。

CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells ('CER-T')..

CERo将这些工程化细胞称为嵌合吞噬受体T细胞（“CER-T”）。

CERo's lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.

CERo公司的主要研究性候选产品CER-1236正在血液系统恶性肿瘤中进行评估。

Forward-Looking Statements

前瞻性陈述

This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed transaction, including its expected timing and completion, the satisfaction of closing conditions and the go-ship process, the anticipated benefits of the proposed transaction to SRX Global and CERo, the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global's and CERo's development strategy and objectives.

本通讯包含适用证券法律定义下的前瞻性陈述。这些陈述包括但不限于，关于拟议交易的陈述，包括其预期时间安排和完成情况、交割条件的满足情况以及上市流程；拟议交易对SRX Global和CERo的预期益处；CER-1236的临床开发、安全性特征、药代动力学和药效学特性、治疗潜力以及未来评估；CERTAIN-T试验的进展、设计和受试者入组；计划的队列扩展和剂量递增；以及SRX Global和CERo的开发战略和目标。

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements..

这些陈述基于当前的预期和假设，并受风险和不确定性的影响，这些因素可能导致实际结果与这些陈述所表达或暗示的结果存在重大差异。

Risks and uncertainties related to the proposed transaction include, among others, the possibility that the transaction is not completed on the anticipated timeline or at all; that the go-shop process results in a superior proposal and the termination of the purchase agreement, including the payment of termination fees; the failure to satisfy closing conditions, including those related to CERo Holdings’ preferred stock; changes in the value or liquidity of SRX common stock issued as consideration; disruption to CERo Therapeutics’ operations, personnel and business relationships; and the risks inherent in the clinical development of CER-1236, an investigational product candidate.

与拟议交易相关的风险和不确定性包括但不限于：交易可能无法按预期时间表完成或根本无法完成；“寻购”流程可能导致出现更优提案并导致购买协议终止，包括支付终止费；未能满足交割条件，包括与CERo Holdings优先股相关的条件；作为对价发行的SRX普通股的价值或流动性发生变化；CERo Therapeutics的运营、人员及业务关系受到干扰；以及候选 investigational 产品CER-1236在临床开发中固有的风险。

Certain risks that could cause actual results to differ are set forth in SRX Global's and CERo's respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein.

可能导致实际结果出现差异的某些风险已在SRX Global和CERo分别向美国证券交易委员会提交的文件中列明，包括其最新的10-K表格年度报告及随后的10-Q表格季度报告，以及其中通过引用并入的文件。

The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law..

上述文件中所述的风险并非详尽无遗。前瞻性陈述并不构成对业绩的保证，不应过度依赖此类陈述。除非法律另有要求，SRX Global 没有义务公开更新或修订任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因。

Company Contact:

公司联系人：

SRX Global Inc.

SRX 全球公司

Kent Cunningham, Chief Executive Officer

肯特·坎宁安，首席执行官

Investor Contact:

投资者联系：

KCSA Strategic Communications

KCSA战略传播

Valter Pinto, Managing Director

瓦尔特·平托，总经理

212-896-1254

212-896-1254